摘要:
An objective of the present invention is to provide compounds having antitumor activity. According to the present invention, there is provided compounds represented by formula (I) and pharmaceutically acceptable salts thereof, and solvates thereof: wherein R1 represents H or a substitutable unsaturated five- or six-membered heterocyclic ring; R2 represents H; X represents CH or N; Z represents O or S; E is absent or represents halogen, alkyl, or alkoxy; J represents S or O; and T represents phenyl, an unsaturated five- or six-membered heterocyclic ring, an unsaturated nine- or ten-membered bicyclic carbocyclic ring or heterocyclic ring.
摘要:
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X═CH or N; Z═O or S; L=O or S; M=CR10R11, wherein R10 and R11═H, alkyl, or alkoxy, NR12 wherein R12═H or alkyl; R1, R2, and R3═H or optionally substituted alkoxy; R4═H; R5-8═H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by —R14, -T-R15, or —NR16R17 wherein T=O, S, or NH; R14=an optionally substituted carbocyclic or heterocyclic ring; and R15-17=alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR18R19 wherein R18 and R19═H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.
摘要翻译:本发明的目的是提供具有有效抗肿瘤活性的化合物。 本发明的化合物由式(I)表示或其药学上可接受的盐或溶剂合物:其中X = CH或N; Z = O或S; L = O或S; M = CR10R11,其中R10和R11 = H,烷基或烷氧基,NR12,其中R12 = H或烷基; R1,R2和R3 = H或任选取代的烷氧基; R4 = H; R5-8 = H,卤素,烷氧基等; 并且R 9 =任选被-R 14,-T-R 15或-NR 16 R 17取代的烷基,其中T = O,S或NH; R14 =任选取代的碳环或杂环; 和R 15-17 =烷基或任选取代的碳环或杂环,或-NR 18 R 19,其中R 18和R 19 = H,任选取代的烷基,或任选取代的碳环或杂环,或任选取代的碳环或杂环。
摘要:
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X=CH or N; Z=O or S; L=O or S; M=CR10R11, wherein R10 and R11=H, alkyl, or alkoxy, NR12 wherein R12=H or alkyl; R1, R2, and R3=H or optionally substituted alkoxy; R4=H; R5-8=H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by —R14, -T-R15, or —NR16R17 wherein T=O, S, or NH; R14=an optionally substituted carbocyclic or heterocyclic ring; and R15-17=alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR18R19 wherein R18 and R19=H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.
摘要翻译:本发明的目的是提供具有有效抗肿瘤活性的化合物。 本发明的化合物由式(I)表示或其药学上可接受的盐或溶剂化物:其中X = CH或N; Z = O或S; L = O或S; M = CR10R11,其中R10和R11 = H,烷基或烷氧基,NR12,其中R12 = H或烷基; R1,R2和R3 = H或任选取代的烷氧基; R4 = H; R5-8 = H,卤素,烷氧基等; 并且R 9 =任选被-R 14,-T-R 15或-NR 16 R 17取代的烷基,其中T = O,S或NH; R14 =任选取代的碳环或杂环; 和R 15-17 =烷基或任选取代的碳环或杂环,或-NR 18 R 19,其中R 18和R 19 = H,任选取代的烷基,或任选取代的碳环或杂环,或任选取代的碳环或杂环。
摘要:
An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR10, CR11R2, carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.
摘要:
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X=CH or N; Z=O or S; L=O or S; M=CR10R11, wherein R10 and R11=H, alkyl, or alkoxy, NR12 wherein R12=H or alkyl; R1, R2, and R3=H or optionally substituted alkoxy; R4=H; R5-8=H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by —R14, -T-R15, or —NR16R17 wherein T=O, S, or NH; R14=an optionally substituted carbocyclic or heterocyclic ring; and R15-17=alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR18R19 wherein R18 and R19=H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.
摘要翻译:本发明的目的是提供具有有效抗肿瘤活性的化合物。 本发明的化合物由式(I)表示或其药学上可接受的盐或溶剂化物:其中X = CH或N; Z = O或S; L = O或S; 其中R 10和R 11 = H,烷基或烷氧基,NR(R 11) 其中R 12 = H或烷基; R 1,R 2和R 3 = H或任选取代的烷氧基; R 4 = H; R 5〜8 = H,卤素,烷氧基等; 和R 9 =任选被-R 14,-TR 15或-NR 16 R 15取代的烷基, 其中T = O,S或NH; R 14是任选取代的碳环或杂环; 和R 15-17 =烷基或任选取代的碳环或杂环,或-NR 18 R 19其中R 18, R 00和R 19 = H,任选取代的烷基,或任选取代的碳环或杂环,或任选取代的碳环或杂环。
摘要:
An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR10, CR11R2, carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.
摘要翻译:本发明的目的是提供对FGF受体家族的自磷酸化具有抑制活性的新型化合物,并且当口服或经受干预时可抑制癌细胞的生长。 本发明的化合物由式(I)表示或其药学上可接受的盐或溶剂合物:其中X表示CH或N; Z表示O或S; Q表示NR 10,CR 11 R 2,羰基,O,S(= O)m,其中m为0至2,或脲; R 1至R 3各自独立地表示其中烷基和烷氧基任选被取代的H,OH,卤素,硝基,氨基,烷基,烷氧基等; R 4表示H; R 5至R 8各自独立地表示H,卤素,烷基或烷氧基; 并且R 9表示任选取代的碳环或杂环基。
摘要:
The present invention relates to a process for producing a 4-quinolone derivative, comprising allowing an o-aminoacetophenone derivative to react with a formic acid in an aprotic solvent in the presence of a suitable base, and adding a protic solvent to the reaction mixture. This is a simple process for producing 4-quinolone derivatives, applicable to large-scale commercial production.
摘要:
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X=CH or N; Z=O or S; L=O or S; M=CR10R11, wherein R10 and R11=H, alkyl, or alkoxy, NR12 wherein R12=H or alkyl; R1, R2, and R3=H or optionally substituted alkoxy; R4=H; R5-8=H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by -T-R15, or —NR16R17 wherein T=O, S, or NH; R14=an optionally substituted carbocyclic or heterocyclic ring; and R15-17=alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR18R19 wherein R18 and R19=H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.
摘要翻译:本发明的目的是提供具有有效抗肿瘤活性的化合物。 本发明的化合物由式(I)表示或其药学上可接受的盐或溶剂化物:其中X = CH或N; Z = O或S; L = 0或S; M = CR10R11,其中R10和R11 = H,烷基或烷氧基,NR12,其中R12 = H或烷基; R1,R2和R3 = H或任选取代的烷氧基; R4 = H; R5-8 = H,卤素,烷氧基等; 并且R 9 =任选被-T-R 15或-NR 16 R 17取代的烷基,其中T = O,S或NH; R14 =任选取代的碳环或杂环; 和R 15-17 =烷基或任选取代的碳环或杂环,或-NR 18 R 19,其中R 18和R 19 = H,任选取代的烷基,或任选取代的碳环或杂环,或任选取代的碳环或杂环。
摘要:
Quinolone derivatives having a quinolone structure: ##STR1## where Yo is O or S are disclosed, which are useful as cardiotonic agents. Typical examples of the quinolone derivatives include: 6,7-dimethoxy-4 (1H) quinolone (compound 6) and 5-hydroxy-6-methoxy-4(1H) quinolone (compound 1) as typical compounds of the formulae[I] and [I'], respectively, shown in the specification.